Faslodex

Faslodex, generically fulvestrant, treats hormone receptor-positive metastatic breast cancer in postmenopausal women post-failure of other anti-estrogen drugs. It acts by degrading estrogen receptors on cancer cells, reducing estrogen-induced cancer growth. Delivered intramuscularly, initially biweekly, then monthly, often in combination therapies, Faslodex enhances progression-free survival. Common side effects include injection pain and fatigue.

Select Wishlist

    Left Menu Icon
    Your Cart